Publication at Faculty of Medicine in Hradec Králové |
2011
Abstract
The article presents our experience with chelatation therapy by deferasirox. It describes a case with MDS 5q-syndrome, in which chelatation therapy by deferasirox brought positive effect on the decrease in ferritin and reduced need for transfusions.
The treatment had also a good effect on reducing liver tests. The next section summarize our experience with chelatation therapy in our group of 16 patients, almost tolerance and adverse events of deferasirox.